Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 9, 2014, Pages 1715-1721

  Tamori, Akihiro ^a   Hino, Masayuki ^a   Kawamura, Etsushi ^a   Fujii, Hideki ^a   Uchida Kobayashi, Sawako ^a   Morikawa, Hiroyasu ^a   Nakamae, Hirohisa ^a   Enomoto, Masaru ^a   Murakami, Yoshiki ^a   Kawada, Norifumi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti HBs; HBV reactivation; HBV DNA; Prospective study

Indexed keywords

ALANINE AMINOTRANSFERASE; ARGININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ENTECAVIR; GLUTAMINE; GLYCINE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; PREDNISOLONE; RITUXIMAB; SERINE; THREONINE; VINCRISTINE; VIRUS DNA; ANTIVIRUS AGENT; GUANINE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ACUTE LEUKEMIA; ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIBODY TITER; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE SEVERITY; FEMALE; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HUMAN; LONG TERM CARE; LYMPHOMA; MALE; MYELODYSPLASTIC SYNDROME; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIRUS REACTIVATION; ANALOGS AND DERIVATIVES; COMPLICATION; HEMATOLOGIC NEOPLASMS; HEPATITIS B VIRUS; HETEROZYGOTE; MIDDLE AGED; PHYSIOLOGY; TIME; TREATMENT WITHDRAWAL; VERY ELDERLY; VIROLOGY; VIRUS ACTIVATION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIVIRAL AGENTS; CARRIER STATE; FEMALE; GUANINE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; VIRUS ACTIVATION; WITHHOLDING TREATMENT;

EID: 84906510777     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12604     Document Type: Article

References (33)

1. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006; 43: S173-181.
2. Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int. 2009; 29: 100-107.
3. Yeo W, Zee B, Zhong S etal. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br. J. Cancer 2004; 90: 1306-1311.
4. Hui CK, Cheung WW, Zhang HY etal. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68.
5. Pei SN, Chen CH, Lee CM etal. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann. Hematol. 2010; 89: 255-262.
6. Onozawa M, Hashino S, Izumiyama K etal. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005; 79: 616-619.
7. Dhédin N, Douvin C, Kuentz M etal. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 1998; 66: 616-619.
8. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49: S156-165.
9. Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin. Gastroenterol. Hepatol. 2006; 4: 1076-1081.
10. Umemura T, Tanaka E, Kiyosawa K, Kumada H, Japan de novo Hepatitis B Research Group. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin. Infect. Dis. 2008; 47: e52-56.
11. Barclay S, Pol S, Mutimer D etal. Erratum to "The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting" [J]. Clin. Virol. 41 (4) 2008 243-254]. J. Clin. Virol. 2008; 42: 104-115.
12. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
13. Oketani M, Ido A, Uto H, Tsubouchi H. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol. Res. 2012; 42: 627-636.
14. Loomba R, Rowley A, Wesley R etal. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann. Intern. Med. 2008; 148: 519-528.
15. Li HR, Huang JJ, Guo HQ etal. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J. Viral Hepat. 2011; 18: 877-883.
16. Chen FW, Coyle L, Jones BE, Pattullo V. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease. Liver Int. 2013; 33: 1203-1210.
17. Allice T, Cerutti F, Pittaluga F etal. COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma. J. Clin. Microbiol. 2007; 45: 828-834.
18. Usuda S, Okamoto H, Tanaka T etal. Differentiation of hepatitis B virus genotypes D and E by ELISA using monoclonal antibodies to epitopes on the preS2-region product. J. Virol. Methods 2000; 87: 81-89.
19. Enomoto M, Tamori A, Kohmoto MT etal. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences. J. Med. Virol. 2007; 79: 1664-1670.
20. Fujiyama A, Miyanohara A, Nozaki C, Yoneyama T, Ohtomo N, Matsubara K. Cloning and structural analyses of hepatitis B virus DNAs, subtype adr. Nucleic Acids Res. 1983; 11: 4601-4610.
21. Viganò M, Vener C, Lampertico P etal. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2011; 46: 125-131.
22. Borentain P, Colson P, Coso D etal. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. J. Viral Hepat. 2010; 17: 807-815.
23. Hammond SP, Borchelt AM, Ukomadu C, Ho VT, Baden LR, Marty FM. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 2009; 15: 1049-1059.
24. Matsue K, Kimura S, Takanashi Y etal. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 2010; 116: 4769-4776.
25. Fukushima N, Mizuta T, Tanaka M etal. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann. Oncol. 2009; 20: 2013-2017.
26. Huang YH, Hsiao LT, Hong YC etal. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J. Clin. Oncol. 2013; 31: 2765-2772.
27. Hsu C, Tsou HH, Lin SJ etal. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology 2013. doi: 10.1002/hep.26718
28. Knöll A, Boehm S, Hahn J, Holler E, Jilg W. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor. J. Viral Hepat. 2007; 14: 478-483.
29. Schubert A, Michel D, Mertens T. Late HBsAg seroreversion of mutated hepatitis B virus after bone marrow transplantation. BMC Infect. Dis. 2013; 13: 223.
30. Tamori A, Koike T, Goto H etal. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J. Gastroenterol. 2011; 46: 556-564.
31. Westhoff TH, Jochimsen F, Schmittel A etal. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102: 1930.
32. Pelizzari AM, Motta M, Cariani E, Turconi P, Borlenghi E, Rossi G. Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies. Hematol. J. 2004; 5: 325-328.
33. Lin PC, Poh SB, Lee MY, Hsiao LT, Chen PM, Chiou TJ. Fatal fulminant hepatitis B after withdrawal of prophylactic lamivudine in hematopoietic stem cell transplantation patients. Int. J. Hematol. 2005; 81: 349-351.